Table 2 Severe adverse events
From: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
Severe AE | CSRN: n = 25 | Non-CSRN: n = 45 |
|---|---|---|
Decreased appetite | 6 (24.0) | 4 (8.8) |
Hepatic ascites | 4 (16.0) | 3 (6.6) |
Hepatic encephalopathy | 3 (12.0) | 2 (4.4) |
Gastrointestinal bleeding | 2 (8.0) | – |
Proteinuria | 2 (8.0) | 1 (2.2) |
Increased blood bilirubin | 1 (4.0) | 1 (2.2) |
Acute pancreatitis | 1 (4.0) | 1 (2.2) |
Rhabdomyolysis | 1 (4.0) | – |
Sepsis | 1 (4.0) | – |
Gastrointestinal perforation | – | 1 (2.2) |
Interstitial pneumonia | – | 1 (2.2) |